公开(公告)号：US10793628B2

公开(公告)日：2020-10-06

申请号：US15322788

申请日：2015-06-30

Applicant: Academia Sinica

Inventor： Wen-Hwa Lee ,  Jin-Yuh Shew ,  Che Ma ,  Chia-Lin Chen ,  Wen-Hsin Lee ,  Chun-Kai Huang ,  Heng-Hsiung Wu

IPC: A61K39/395 ,  C07K16/24 ,  A61K45/06 ,  A61K31/713 ,  A61K38/20 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C07K14/715 ,  C12N15/113 ,  A61K39/00

Abstract: Methods and compositions for treatment and therapy of cancer are provided. Specifically, antagonists specific for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B are provided. Potent neutralizing antibodies specific for IL-17RB and methods for their manufacture and use are disclosed. The invention also relates to antisense, RNAi and shRNA compositions for the prevention and treatment of cancer, in particular breast cancer and pancreatic cancer.

公开(公告)号：US11672853B2

公开(公告)日：2023-06-13

申请号：US16431099

申请日：2019-06-04

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Che Ma ,  Cheng-Chi Wang ,  Juine-Ruey Chen

IPC: A61K39/145 ,  C12N7/00 ,  A61K39/12 ,  C07K16/10 ,  A61K39/00

CPC classification number: A61K39/145 ,  A61K39/12 ,  C07K16/1018 ,  C12N7/00 ,  A61K2039/55505 ,  C07K2317/76 ,  C12N2740/11034 ,  C12N2740/16034 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2770/24134 ,  Y02A50/30

Abstract: Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41.

公开(公告)号：US10307475B2

公开(公告)日：2019-06-04

申请号：US14182296

申请日：2014-02-18

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Che Ma ,  Cheng-Chi Wang ,  Juine-Ruey Chen

IPC: A61K39/145 ,  C12N7/00 ,  A61K39/12 ,  C07K16/10 ,  A61K39/00

Abstract: Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41.

公开(公告)号：US20150344544A1

公开(公告)日：2015-12-03

申请号：US14723297

申请日：2015-05-27

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Chung-Yi Wu ,  Che Ma

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/24 ,  C07K16/10 ,  A61K39/42 ,  A61K39/395 ,  A61K45/06 ,  C07K16/32

CPC classification number: C12P19/14 ,  A61K39/3955 ,  A61K39/42 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/1018 ,  C07K16/18 ,  C07K16/241 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C12N9/24 ,  C12Y302/01 ,  C12Y302/01051 ,  Y02A50/412 ,  Y02A50/466

Abstract: The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2. The glycoengineered Fc region binds FcγRIIA or FcγRIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Abstract translation: 本公开涉及包含糖工程化Fc区的糖蛋白，特别是单克隆抗体，其中所述Fc区包含具有Sia2（α2-6）Gal2GlcNAc2Man3GlcNAc2结构的优化的N-聚糖。 相对于包含野生型Fc区域的可比较的单克隆抗体，糖工程化Fc区域以更高的亲和力结合FcγRIIA或FcγRIIIA。 本发明的单克隆抗体特别可用于预防，治疗或改善与需要由FcγR介导的效应细胞功能（例如，ADCC）增强的功效的疾病，病症或感染相关的一种或多种症状，例如， 癌症，自身免疫性，感染性疾病，以及提高其作用由ADCC介导的治疗性抗体的治疗功效。

公开(公告)号：US12257298B2

公开(公告)日：2025-03-25

申请号：US18005573

申请日：2022-04-12

Applicant: ACADEMIA SINICA

Inventor： Che Ma ,  Chi-Huey Wong ,  Han-Yi Huang

IPC: A61K39/215 ,  A61P31/04 ,  A61K39/00

Abstract: The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.

公开(公告)号：US10118969B2

公开(公告)日：2018-11-06

申请号：US15011544

申请日：2016-01-30

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Che Ma ,  Han-Chung Wu

IPC: C12N9/24 ,  C07K16/30 ,  C07K16/28 ,  A61K45/06 ,  C07K16/10 ,  C07K16/32 ,  C07K16/18 ,  C12P21/00

Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.

公开(公告)号：US20160348144A1

公开(公告)日：2016-12-01

申请号：US15164968

申请日：2016-05-26

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Che Ma ,  Yung-Chieh Tseng

IPC: C12P21/00 ,  C12N7/00

CPC classification number: C12P21/005 ,  A61K39/12 ,  A61K39/145 ,  C07K14/005 ,  C12N7/00 ,  C12N2760/16111 ,  C12N2760/16121 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12Y302/01096 ,  G01N2333/00 ,  G01N2333/11 ,  Y02A50/386 ,  Y02A50/394 ,  Y02P20/52

Abstract: Methods for production of virus particles with simplified glycosylation on structural or surface proteins are provided. When used as targets for vaccine production, the conserved nature of such sites generates vaccines that are less sensitive to viral mutations. Use of glycosylation inhibitors for production of viruses with simplified glycosylation profiles are disclosed. An exemplary disclosure of influenza viruses and methods for production of mono-glycosylated influenza virus particles is provided. Methods for production of mono-glycosylated forms of influenza A virus, NIBRG-14 (H5N1) are provided.

Abstract translation: 提供了在结构或表面蛋白上生成具有简化糖基化的病毒颗粒的方法。 当用作疫苗生产的目标时，这些位点的保守性质产生对病毒突变较不敏感的疫苗。 公开了糖基化抑制剂用于产生具有简化糖基化特征的病毒的用途。 提供流感病毒的示例性公开和用于生产单糖基化流感病毒颗粒的方法。 提供了甲型流感病毒，NIBRG-14（H5N1）单糖基化形式的生产方法。

公开(公告)号：US11918641B2

公开(公告)日：2024-03-05

申请号：US17998208

申请日：2021-05-07

Applicant: ACADEMIA SINICA

Inventor： Chi-Huey Wong ,  Hsin-Yu Liao ,  Shih-Chi Wang ,  Yi-An Ko ,  Kuo-I Lin ,  Che Ma ,  Ting-Jen Cheng

IPC: A61K39/145 ,  A61K35/76 ,  A61K39/00 ,  A61K39/12 ,  A61P31/16 ,  C07K14/005 ,  C07K14/11

CPC classification number: A61K39/145 ,  A61P31/16 ,  C07K14/005 ,  A61K2039/575

Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

公开(公告)号：US20200046826A1

公开(公告)日：2020-02-13

申请号：US16431099

申请日：2019-06-04

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Che Ma ,  Cheng-Chi Wang ,  Juine-Ruey Chen

IPC: A61K39/145 ,  A61K39/12 ,  C07K16/10 ,  C12N7/00

Abstract: Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41.

公开(公告)号：US10023892B2

公开(公告)日：2018-07-17

申请号：US14723297

申请日：2015-05-27

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Che Ma

IPC: C07K16/00 ,  C12P19/14 ,  A61K39/395 ,  A61K39/42 ,  A61K45/06 ,  C07K16/10 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N9/24 ,  C07K16/18 ,  A61K39/00

Abstract: The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2. The glycoengineered Fc region binds FcγRIIA or FcγRIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.